Navigation Links
Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56

PRINCETON, N.J., Jan. 26, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported GAAP earnings for its fourth quarter ended December 31, 2010 of $0.45 per diluted share.  Included in fourth quarter results is $0.22 per diluted share in costs from the previously-announced fourth quarter restructuring actions, partially offset by a gain of $0.11 per diluted share from favorable income tax resolutions in the quarter. Excluding these items, earnings per diluted share were $0.56 in the quarter.  For the full-year, earnings per diluted share were $1.06 on a GAAP basis, inclusive of $1.15 per diluted share non-cash impairment charge incurred in the third quarter, $0.21 per diluted share in costs associated with restructuring charges incurred in the fourth quarter, partially offset by a gain of $0.27 per diluted share from favorable income tax resolutions during the year.  Excluding these items, full-year earnings per diluted share were $2.15.  

"During a challenging 2010, we made progress on a number of fronts, including entering into a comprehensive strategic alliance with sanofi-aventis (which helped drive annual backlog growth of 27%), significantly lowering our cost structure, and delivering full-year net revenue growth of 3.1%," said Joe Herring, Chairman and Chief Executive Officer.  "In the fourth quarter, on a sequential basis, revenue grew 3.0% to $492 million and operating margin (after excluding $18.4 million from the fourth quarter restructuring actions) expanded 70 basis points to 9.6%.  Early Development's revenue increased $14 million sequentially and pro forma operating margin grew 130 basis points sequentially to 12.0% reflecting two months of results from our new Porcheville, France and Alnwick, UK sites and modest improvement in toxicology from the depressed third quarter level. As expected, Late-Stage Development revenues and pron of long-term debt45,000-Income taxes payable28,82714,272Total Current Liabilities499,174402,744Long-term debt87,500-Deferred income taxes30,53198,945Other liabilities68,51662,251Total Liabilities685,721563,940Stockholders' Equity:Common stock774764Paid-in capital639,341587,995Retained earnings1,373,7051,305,451Accumulated other comprehensive income (loss)277(5,281)Treasury stock(734,276)(477,925)Total Stockholders' Equity1,279,8211,411,004Total Liabilities and Stockholders'  Equity$
,974,944COVANCE INC.CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE YEARS ENDED DECEMBER 31, 2010 AND 2009(Dollars in thousands)Years Ended December 3120102009Cash flows from operating activities:  Net income$   68,254$ 175,882  Adjustments to reconcile net income to net cash provided byoperating activities:Depreciation and amortization103,02491,289Asset impairment charges119,229-Non-cash compensation expense associated with employee benefitand stock compensation plans32,28926,949Deferred income tax (benefit) provision(71,661)33,030Gain on sale of businesses-(9,681)Loss on disposal of property and equipment1,487998Equity investee earnings(807)(907)Changes in operating assets and liabilities, net of businessesacquired and sold:Accounts receivable23,959(54,937)Unbilled services6,55015,724Inventory(1,998)(12,720)Accounts payable(2,755)(5,163)Accrued liabilities20,097(8,072)Unearned revenue19,4114,174Income taxes payable14,797(1,176)Other assets and liabilities, net2,5473,699Net cash provided by operating activities334,423259,089Cash flows from investing activities:  Capital expenditures(126,278)(131,079)  Acquisition of businesses, net of cash acquired(20,994)(28,096)  Proceeds from sale of businesses-10,373  Other, net4729Net cash used in investing activities(147,225)(148,773)Cash flows from financing activities:  Net borrowings (repayments) under revolving credit facility35,000(50,000)  Borrowings under long-term debt100,000-  Repayments under long-term debt(2,500)-  Stock issued under employee stock purchase and option plans18,82510,682  Purchase of treasury stock(256,351)(4,828)  Payment of debt assumed upon acquisition of business-(5,431)Net cash used in financing activities(105,026)(49,577)Effect of exchange rate changes on cash5,5827,396Net change in cash and cash equivalents87,75468,135Cash and cash equivalents, beginning of period289,469221,334Cash and cash equivalents, end of period$ 377,223$ 289,469COVANCE INC.GAAP to Pro Forma ReconciliationQ4 2010(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAPFourth Quarter Restructuring Activities (1)Income Tax Items (2)Pro FormaNet revenues$
491,513Reimbursable out-of-pocket expenses27,94227,942Total revenues519,455--519,455Costs and expenses:  Cost of revenue346,924346,924  Reimbursable out-of-pocket expenses27,94227,942  Selling, general and administrative89,810(18,092)71,718  Depreciation and amortization25,919(270)25,649  Asset impairment charges--Total costs and expenses490,595(18,362)-472,233Income from operations28,86018,362-47,222Other expense (income), net:  Interest expense (income), net430430  Foreign exchange transaction loss, net1,0541,054  Gain on sale of businesses--Other expense (income), net1,484--1,484Income before taxes and equity investee earnings27,37618,362-45,738Tax (benefit) expense(1,121)4,6746,94610,499Equity investee (loss) earnings(119)(119)Net income $
35,120Basic earnings per share$
.57Weighted average shares outstanding - basic61,390,96561,390,96561,390,96561,390,965Diluted earnings per share$
.56Weighted average shares outstanding - diluted62,703,69062,703,69062,703,69062,703,690(1) Represents costs incurred in connection with capacity rationalization and cost reduction actions.(2) Represents favorable resolutions of income tax matters during the three months ended December 31, 2010.COVANCE INC.GAAP to Pro Forma ReconciliationFor the year ended December 31, 2010(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAPAsset Impairment and Restructuring Activities
(1)Income Tax Items (2)Pro FormaNet revenues$ 1,925,630$ 1,925,630Reimbursable out-of-pocket expenses112,843112,843Total revenues2,038,473--2,038,473Costs and expenses:  Cost of revenue1,348,4981,348,498  Reimbursable out-of-pocket expenses112,843112,843  Selling, general and administrative307,386(18,092)289,294  Depreciation and amortization103,024(270)102,754  Asset impairment charges119,229(119,229)-Total costs and expenses1,990,980(137,591)-1,853,389Income from operations47,493137,591-185,084Other expense (income), net:  Interest expense (income), net5252  Foreign exchange transaction loss, net3,6493,649  Gain on sale of businesses--Other expense (income), net3,701--3,701Income before taxes and equity investee earnings43,792137,591-181,383Tax (benefit) expense(23,655)49,98117,29843,624Equity investee earnings807807Net income $
38,566Basic earnings per share$
2.20Weighted average shares outstanding - basic63,043,56163,043,56163,043,56163,043,561Diluted earnings per share$
2.15Weighted average shares outstanding - diluted64,472,32664,472,32664,472,32664,472,326(1) Represents third quarter asset impairment charges totaling $119,229 and fourth quarter restructuring costs totaling $18,362.(2) Represents favorable resolutions of income tax matters during the year ended December 31, 2010.COVANCE INC.GAAP to Pro Forma ReconciliationFor the year ended December 31, 2009(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAPIncome Tax Items
(1)Gain on Sale of Businesses (2)Pro FormaNet revenues$ 1,867,634$ 1,867,634Reimbursable out-of-pocket expenses94,99294,992Total revenues1,962,626--1,962,626Costs and expenses:  Cost of revenue1,277,1421,277,142  Reimbursable out-of-pocket expenses94,99294,992  Selling, general and administrative270,593270,593  Depreciation and amortization91,28991,289  Asset impairment charges--Total costs and expenses1,734,016--1,734,016Income from operations228,610--228,610Other expense (income), net:  Interest expense (income), net201201  Foreign exchange transaction loss, net245245  Gain on sale of businesses(9,681)9,681-Other expense (income), net(9,235)-9,681446Income before taxes and equity investee earnings237,845-(9,681)228,164Tax expense62,8702,072(3,388)61,554Equity investee earnings907907Net income $
7,517Basic earnings per share$
2.62Weighted average shares outstanding - basic63,818,71763,818,71763,818,71763,818,717Diluted earnings per share$
2.60Weighted average shares outstanding - diluted64,341,08464,341,08464,341,08464,341,084(1) Represents favorable resolutions of income tax matters during the year ended December 31, 2009.(2) Includes a $9,026 gain on sale of Interactive Voice & Web Response Services ($5,867 net of tax) and a $655 gain on sale of Cardiac Safety Services ($426 net of tax). o forma operating margins were essentially flat with the third quarter levels.

"On the commercial front, solid fourth quarter business awards in Late-Stage Development led to adjusted net orders of $603 million, representing an adjusted book-to-bill ratio of 1.23 to 1. Also signed in the fourth quarter, but not included in our adjusted net orders (consistent with our practice), was a $125 million expansion and extension of an existing dedicated space toxicology agreement from a top ten pharmaceutical client.  

"In the first quarter of 2011, we expect a slight increase in net revenues from the fourth quarter level, largely from higher levels of business under our alliance with sanofi-aventis.  First quarter pro forma earnings per share are expected to be in the range of $0.56 to $0.59, as incremental earnings from higher revenue levels, incremental sequential savings from the fourth quarter restructuring, and a full quarter impact of the share repurchase are expected to be offset by an expense increase of approximately $0.05 per share for incentive compensation accruals returning to normalized levels, and also by increased operating losses related to the transition of services from Vienna, Virginia to Greenfield, Indiana. Looking to the full-year 2011, Covance expects single digit percentage revenue growth and pro forma earnings per share to be in the range of $2.50 to $2.90 per diluted share, excluding costs associated with ongoing restructuring activities.  This range assumes no new strategic alliances with clients and foreign exchange rates remain at year-end 2010 levels."  Consolidated Results($ in millions except EPS)4Q104Q09ChangeFY2010FY2009ChangeTotal Revenues



$1,962.6Less: Reimbursable Out-of-Pockets  



$95.0Net Revenues






3.1 %Operating Income






(79.2)%   Operating Margin %



12.2%Net Income


$ 41.5




(61.2)%Diluted EPS


$ 0.64



$ 2.73

(61.3)%Impairment charge*



-Restructuring Costs*



-Operating Income, excluding items*






(19.0)%  Operating Margin %, ex items*



12.2%Favorable Income Tax Items*



$2.1Gain on Sale, net of tax*



$6.3Net Income, excluding items*






(17.3)%Diluted EPS, excluding items*






(17.5)%* See attached pro forma income statement for reconciliation of GAAP to Pro Forma amounts.Operating Segment Results Early Development($ in millions)4Q10  4Q09ChangeFY2010FY2009ChangeNet Revenues





$ 791.8

6.1%Operating Income (Loss)


$ 23.1



$ 99.7

(132.1)%Operating Margin %



12.6%Q4 Restructuring



-Q2 Cost Actions



-Impairment charge



-Pro Forma Operating Income

$ 26.6




$ 99.7

1.0%Pro Forma OM%



12.6%The Company's Early Development segment includes preclinical toxicology, analytical chemistry, clinical pharmacology services, discovery support, and research products.  Early Development net revenues for the fourth quarter of 2010 were $220.6 million compared to $203.1 million in the fourth quarter of 2009 and $206.5 million last quarter.  The sequential increase in revenue was primarily driven by the inclusion of two full months of results from our Alnwick and Porcheville sites as well as from modest improvement in our toxicology services in the fourth quarter.  Full year 2010 net revenues increased 6.1% to $840.3 million compared to $791.8 million in 2009.  

Operating income for the fourth quarter was $21.1 million and included $5.4 million in costs associated with our fourth quarter restructuring actions. Operating income, excluding these costs, was $26.6 million, compared to $22.0 million last quarter and $23.1 million in the fourth quarter of last year. Operating margins for the fourth quarter, excluding the fourth quarter restructuring actions, were 12.0% compared to 10.7% last quarter and 11.3% in the fourth quarter of 2009. Sequentially, the expansion in operating margins was driven by results from our Alnwick and Porcheville sites, and modest improvement in toxicology services, partially offset by a decline in clinical pharmacology profitability, which was again impacted by study delays.  Full year operating margins were 12.0% compared to 12.6% in the prior year.  

Late-Stage Development($ in millions)4Q104Q09ChangeFY2010FY2009ChangeNet Revenues

$ 270.9





0.9%Operating Income

$ 47.6

$  63.8




(11.4)%Operating Margin %



23.7%Q4 Restructuring

$  (7.1)


-Q2 Cost Actions



-Pro Forma Operating Income

$  54.7

$  63.8



$  254.5

(8.5)%Pro Forma OM%



23.7%The Late-Stage Development segment includes central laboratory, Phase II-III clinical development, and commercialization services (periapproval and market access services).  Late-Stage Development net revenues for the fourth quarter of 2010 were, as expected, essentially flat from last quarter at $270.9 million, a decline of 3.9% year-on-year.  Late-Stage Development services are being negatively impacted by a longer duration between the time a project is awarded and revenue generation begins, a higher level of project scope reductions and cancellations in 2010, and a shifting mix of central lab tests performed and kits returned. For the full year 2010, net revenues grew 0.9% to $1,085.3 million compared to $1,075.8 million in 2009.  

Operating income for the fourth quarter was $47.6 million and included $7.1 million in costs associated with our fourth quarter restructuring actions. Operating income, excluding these costs, was $54.7 million, compared to $55.2 million last quarter and $63.8 million in the fourth quarter of the prior year. Pro forma operating margins were 20.2% for the fourth quarter of 2010 compared to 20.4% last quarter and 22.6% in the fourth quarter of last year. Late-stage margins continue to be impacted by the longer time period between project award and commencement of revenue, higher levels of project scope reductions and cancellations, and the testing mix and geographic mix of kit receipts in central laboratories. Full year pro forma operating margins were 21.5% compared to 23.7% in the prior year.  

Corporate InformationThe Company's backlog at December 31, 2010 grew 27.3% year-over-year to $6.2 billion compared to $6.0 billion at September 30, 2010 and $4.87 billion at December 31, 2009.  Foreign exchange positively impacted sequential backlog growth by $12 million.  Adjusted net orders (net orders adjusted for contracts with minimum volume commitments) were $603 million in the fourth quarter of 2010.

Corporate expenses totaled $39.9 million in the fourth quarter of 2010 compared to $33.4 million last quarter and $32.0 million in the fourth quarter of last year.  Fourth quarter corporate expenses included $5.8 million in costs associated with our recently announced restructuring actions.  We expect corporate expenses as a percent of revenue, excluding severance and other restructuring costs, to trend lower during 2011 as the savings from the planned restructuring actions are realized.

Cash and cash equivalents at December 31, 2010 were $377 million compared to $389 million at September 30, 2010 and $289 million at December 31, 2009.  During the fourth quarter, the Company spent $250 million to repurchase shares of its outstanding common stock and has $133 million in debt outstanding resulting from borrowings related to the accelerated share repurchase.

Free cash flow (defined as operating cash flow less capital expenditures) for the fourth quarter of 2010 was $119 million, consisting of operating cash flow of $145 million less capital expenditures of $26 million.  Free cash flow in 2010 was $208 million, consisting of operating cash flow of $334 million less capital expenditures of $126 million.  In 2011, we expect free cash flow to be approximately $100 million, consisting of operating cash flow of approximately $240 million less capital expenditures of approximately $140 million.  The free cash flow target for 2011 assumes net Days Sales Outstanding (DSO) of approximately 40 days.

Net Days Sales Outstanding (DSO) were 31 days at December 31, 2010 compared to 45 days at September 30, 2010 and 40 days at December 31, 2009.

Taxes in the fourth quarter included a benefit of $6.9 million, primarily as a result of the favorable resolution of an income tax matter. The tax rate for the quarter excluding this benefit and the tax benefit associated with the fourth quarter restructuring costs was 23.0%.

The Company's investor conference call will be webcast on January 27 at 9:00 am ET.  Management's commentary and presentation slides will be available through  

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.9 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.

Financial Exhibits Follow

COVANCE INC.CONSOLIDATED INCOME STATEMENTSFOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2010 AND 2009(Dollars in thousands, except per share data)Three Months Ended December 31Years Ended December 312010200920102009(UNAUDITED)Net revenues$
485,065$ 1,925,630$ 1,867,634Reimbursable out-of-pocket expenses27,94222,263112,84394,992Total revenues519,455507,3282,038,4731,962,626Costs and expenses:  Cost of revenue346,924337,8961,348,4981,277,142  Reimbursable out-of-pocket expenses27,94222,263112,84394,992  Selling, general and administrative89,81067,544307,386270,593  Depreciation and amortization25,91924,753103,02491,289  Asset impairment charges--119,229-Total costs and expenses490,595(a)


1,734,016Income from operations28,860(a)


228,610Other expense (income), net:  Interest expense (income), net430(57)52201  Foreign exchange transaction loss, net1,0543533,649245  Gain on sale of businesses---(9,681)Other expense (income), net1,4842963,701(9,235)(c)Income before taxes and equity investee earnings27,376(a)


237,845(c)Tax (benefit) expense (1,121)(a)


62,870(c)Equity investee (loss) earnings(119)779807907Net income $


75,882(c)Basic earnings per share$


2.76(c)Weighted average shares outstanding - basic61,390,96563,968,68263,043,56163,818,717Diluted earnings per share$


2.73(c)Weighted average shares outstanding - diluted62,703,69064,541,06364,472,32664,341,084(a) Includes $18,362 in restructuring costs ($13,688 net of tax) and $6,946 in favorable income tax items during the three months ended December 31, 2010.(b) Includes asset impairment charges ($119,229) and restructuring costs ($18,362) totaling $137,591 ($87,610 net of tax) and favorable income tax itemstotaling $17,298 during the year ended December 31, 2010.(c) Includes a $9,026 gain on sale of Interactive Voice & Web Response Services ($5,867 net of tax) and a $655 gain on sale of Cardiac SafetyServices ($426 net of tax) and favorable income tax items totaling $2,072 during the year ended December 31, 2009.Excluding the impact of the asset impairment charges, restructuring charges, favorable income tax items and gain on sale of businesses:Income before taxes and equity investee earnings$
228,164Taxes on income$
,554Net income $
7,517Basic earnings per share$
2.62Diluted earnings per share$
2.60COVANCE INC.CONSOLIDATED BALANCE SHEETSDECEMBER 31, 2010 and 2009(Dollars in thousands)December 31December 3120102009ASSETSCurrent Assets:Cash & cash equivalents$
289,469Accounts receivable, net261,160285,119Unbilled services90,72997,279Inventory82,92480,926Deferred income taxes35,64831,512Prepaid expenses and other current assets98,12793,367Total Current Assets945,811877,672Property and equipment, net843,983921,995Goodwill, net127,653127,653Other assets48,09547,624Total Assets$
,974,944LIABILITIES and STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$
36,834Accrued payroll and benefits107,572111,365Accrued expenses and other current liabilities97,39573,383Unearned revenue186,301166,890Short-term debt and current porti

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Covance Receives Highest Level of Phase I Accreditation
3. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
4. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
5. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
6. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
7. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
8. Covance To Present At The 20th Annual Global Healthcare Services Conference
9. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
10. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  "They really did ... of her Kaiser Permanente care team, after a routine ... treatment plan for cancer. The 79-year-old Kaiser Permanente Senior ... , went in for what she thought was tendinitis ... physician and care team, however, she was diagnosed with ...
(Date:10/8/2015)...  Trovagene, Inc., (NASDAQ:   TROV) a developer ... of results from a field experience analysis featuring ... (PCM) platform to accurately identify mutational status, ... appropriate therapy for patients. Mark Erlander , ... the results today in an oral presentation titled ...
(Date:10/8/2015)... York , October 8, 2015 ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 ... valued at USD 2.63 billion in 2013 and is anticipated ... 2022 to reach USD 4.00 billion in 2022. --> ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ...
Breaking Medicine Technology:
... Calif., May 17, 2012   Accuray Incorporated (Nasdaq: ... announced today the appointment of Richard Pettingill, LFACHE as ... May 11, 2012.   Richard Pettingill,s career ... leadership positions in a variety of prominent organizations. Most ...
... 2012 Simbionix USA Corporation, the ... education products, is proud to announce the release ... GI Mentor™ Express simulator and the ...      (Logo: ...
Cached Medicine Technology:
(Date:10/9/2015)... ... ... For many, October is a month whose focus has long been on ... cure. At Beverly Hills Physicians in Southern California, it is also a time to ... Beverly Hills Physicians is encouraging patients and non-patients alike to donate their new and ...
(Date:10/9/2015)... Nashville, TN (PRWEB) , ... October 09, 2015 ... ... one of three best audiologists in The Tennessean's eighth annual Toast of Music ... play. , Local Nashville residents nominated and cast votes for their favorite ...
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation of America ... Control and Prevention (CDC) to improve the knowledge and skills of underserved adults with ... a project by the CDC and allows AAFA to continue vital efforts to educate ...
(Date:10/9/2015)... Australia (PRWEB) , ... October 09, 2015 , ... ... in an upcoming episode of Innovations with Ed Begley Jr., airing 1st QT ... segment, Innovations will educate audiences on MMJ Phytotech Limited (MMJ) – a global ...
(Date:10/9/2015)... Maryland (PRWEB) , ... October 09, 2015 , ... ... and assisted living placement counseling, recently opened its newest office in Maryland – ... senior care industry with a background as a project management technology consultant to ...
Breaking Medicine News(10 mins):
... ... identification methods produce inaccurate results; relationship models are more effective than bibliometric lists in ... ... generally-held notion that scientists who are “productive” in terms of publishing are well connected ...
... , CHICAGO , Jan. 28 Code ... Express, Inc., a portfolio investment of CHS Private Equity V ... New York -based private equity firm.   , Suture Express ... medical and surgical products.  Suture Express offers over 1,600 acute ...
... known that smokers damage their health by directly inhaling ... access journal Environmental Health has shown that ... smoke, contrary to the prevailing assumption that such risks ... actually smoking. Maria Teresa Piccardo worked with a ...
... ... ... -- Celebrity doctors attract high-value patients, get book deals, CNN expert spots, lucrative speaking engagements, ... and branding experts report high-visibility doctors are as adept at publicity and personal branding as ...
... Jan. 28 Grubb & Ellis Healthcare REIT II, ... to acquire Highlands Ranch Medical Pavilion, an approximately 37,000-square-foot, multi-tenant ... Highlands Ranch .  The acquisition is subject to customary ... in the agreement.   , Located at 8671 S. Quebec ...
... YORK , Jan. 28 Care Investment Trust Inc. ... estate investment and finance company formed to invest in healthcare-related real ... Liquidation (the "Plan"), previously approved by the Company,s Board of Directors ... at a special meeting called for that purpose.  Approval of the ...
Cached Medicine News:
... latest addition to our suite ... is the personal-sized GeneAmp PCR ... for both basic PCR and ... the culmination of several years ...
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
... The Techne TC412 is a high performance, ... price. Features & Benefits include: Flexible ... intuituve programming, 8 peltiers, PC networking. Includes ... Up to 32 Techne cyclers can be connected ...
Medicine Products: